{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:09:27Z","timestamp":1789463367899,"version":"build-2803163510"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04163-y","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:36:44Z","timestamp":1786513004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The \u201cobesity paradox\u201d in dosing: a comprehensive analytical review of cockcroft\u2013gault versus CKD-EPI for predicting clearance of narrow-therapeutic-index drugs in patients with BMI\u2009>\u200940\u00a0kg\/m\u00b2"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-1745","authenticated-orcid":false,"given":"Arbind Kumar","family":"Choudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"4163_CR1","volume-title":"Obesity and overweight fact sheet","author":"World Health Organization","year":"2024","unstructured":"World Health Organization (2024) Obesity and overweight fact sheet. WHO, Geneva"},{"key":"4163_CR2","volume-title":"National Health and Nutrition Examination Survey 2017-March 2020 prepandemic data files. NCHS Reports No. 158","author":"B Stierman","year":"2021","unstructured":"Stierman B, Afful J, Carroll MD et al (2021) National Health and Nutrition Examination Survey 2017-March 2020 prepandemic data files. NCHS Reports No. 158. NCHS, Hyattsville, MD"},{"key":"4163_CR3","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL (2020) Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018. NCHS, Hyattsville, NCHS Data Brief No 360"},{"issue":"25","key":"4163_CR4","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","volume":"381","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Bleich SN, Cradock AL et al (2019) Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 381(25):2440\u20132450","journal-title":"N Engl J Med"},{"issue":"7 Suppl","key":"4163_CR5","first-page":"s176","volume":"22","author":"CM Apovian","year":"2016","unstructured":"Apovian CM (2016) Obesity: definition, comorbidities, causes, and burden. Am J Manag Care 22(7 Suppl):s176\u2013s185","journal-title":"Am J Manag Care"},{"issue":"2","key":"4163_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","volume":"49","author":"MJ Hanley","year":"2010","unstructured":"Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71\u201387","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4163_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","volume":"39","author":"G Cheymol","year":"2000","unstructured":"Cheymol G (2000) Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 39(3):215\u2013231","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4163_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJE Brill","year":"2012","unstructured":"Brill MJE, Diepstraten J, van Rongen A et al (2012) Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 51(5):277\u2013304","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4163_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","volume":"32","author":"MP Pai","year":"2012","unstructured":"Pai MP (2012) Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 32(9):856\u2013868","journal-title":"Pharmacotherapy"},{"issue":"1","key":"4163_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00134-003-2059-6","volume":"30","author":"BL Erstad","year":"2004","unstructured":"Erstad BL (2004) Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 30(1):18\u201332","journal-title":"Intensive Care Med"},{"issue":"5","key":"4163_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.18773\/austprescr.2017.053","volume":"40","author":"M Barras","year":"2017","unstructured":"Barras M, Legg A (2017) Drug dosing in obese adults. Aust Prescr 40(5):189\u2013193","journal-title":"Aust Prescr"},{"issue":"5","key":"4163_CR12","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1053\/j.ackd.2010.05.010","volume":"17","author":"MP Pai","year":"2010","unstructured":"Pai MP (2010) Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 17(5):e53\u2013e62","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"4163_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","volume":"14","author":"C Smit","year":"2018","unstructured":"Smit C, De Hoogd S, Br\u00fcggemann RJM, Knibbe CAJ (2018) Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol 14(3):275\u2013285","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"4163_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37(3):840\u2013851","journal-title":"Crit Care Med"},{"issue":"suppl 7","key":"4163_CR15","first-page":"S456","volume":"59","author":"MP Pai","year":"2014","unstructured":"Pai MP, Bertino JS Jr (2014) Pharmacology and pharmacokinetic considerations for antibiotic dosing in obese patients. Clin Infect Dis 59(suppl 7):S456\u2013S462","journal-title":"Clin Infect Dis"},{"key":"4163_CR16","volume-title":"Pharmacokinetics in patients with impaired renal function\u2014guidance for industry","author":"U.S. Food and Drug Administration","year":"2020","unstructured":"U.S. Food and Drug Administration (2020) Pharmacokinetics in patients with impaired renal function\u2014guidance for industry. FDA, Silver Spring, MD"},{"key":"4163_CR17","volume-title":"Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency (2015) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. EMA, London"},{"issue":"1","key":"4163_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/archinte.165.1.55","volume":"165","author":"JP Curtis","year":"2005","unstructured":"Curtis JP, Selter JG, Wang Y et al (2005) The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 165(1):55\u201361","journal-title":"Arch Intern Med"},{"issue":"3","key":"4163_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD (2003) Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63(3):793\u2013808","journal-title":"Kidney Int"},{"issue":"5","key":"4163_CR20","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1681\/ASN.2015030252","volume":"27","author":"P Stenvinkel","year":"2016","unstructured":"Stenvinkel P, Gillespie IA, Tunks J et al (2016) Inflammation modifies the paradoxical association between body mass index and mortality in hemodialysis patients. J Am Soc Nephrol 27(5):1479\u20131486","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4163_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-012-0059-5","volume":"3","author":"M Lainscak","year":"2012","unstructured":"Lainscak M, von Haehling S, Doehner W, Anker SD (2012) The obesity paradox in chronic disease: facts and numbers. J Cachexia Sarcopenia Muscle 3(1):1\u20134","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"4163_CR22","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/ijo.2017.99","volume":"41","author":"HR Banack","year":"2017","unstructured":"Banack HR, Stokes A (2017) The \u2018obesity paradox\u2019 may not be a paradox at all. Int J Obes 41(8):1162\u20131163","journal-title":"Int J Obes"},{"issue":"1","key":"4163_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2012.113905","volume":"309","author":"KM Flegal","year":"2013","unstructured":"Flegal KM, Kit BK, Orpana H, Graubard BI (2013) Association of all-cause mortality with overweight and obesity using standard BMI categories: a systematic review and meta-analysis. JAMA 309(1):71\u201382","journal-title":"JAMA"},{"issue":"3","key":"4163_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1345\/aph.1Q374","volume":"46","author":"EJ Park","year":"2012","unstructured":"Park EJ, Pai MP, Dong T et al (2012) The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother 46(3):317\u2013328","journal-title":"Ann Pharmacother"},{"issue":"1","key":"4163_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1053\/j.ajkd.2009.03.008","volume":"54","author":"LA Stevens","year":"2009","unstructured":"Stevens LA, Nolin TD, Richardson MM et al (2009) Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 54(1):33\u201342","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4163_CR26","first-page":"31","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341","journal-title":"Nephron"},{"issue":"9","key":"4163_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"19","key":"4163_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749","journal-title":"N Engl J Med"},{"issue":"2","key":"4163_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","volume":"79","author":"C Delgado","year":"2022","unstructured":"Delgado C, Baweja M, Crews DC et al (2022) A unifying approach for GFR estimation: NKF-ASN Task Force recommendations. Am J Kidney Dis 79(2):268\u2013288","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"4163_CR30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/FTD.0000000000000090","volume":"36","author":"A Khanal","year":"2014","unstructured":"Khanal A, Castelino RL, Peterson GM, Jose MD (2014) Use of eGFR equations for drug dosing: a survey of Australian and New Zealand hospitals. Ther Drug Monit 36(6):765\u2013770","journal-title":"Ther Drug Monit"},{"issue":"2","key":"4163_CR31","first-page":"99","volume":"7","author":"GB Forbes","year":"1983","unstructured":"Forbes GB, Welle SL (1983) Lean body mass in obesity. Int J Obes 7(2):99\u2013107","journal-title":"Int J Obes"},{"issue":"2","key":"4163_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/ajcn\/52.2.214","volume":"52","author":"SB Heymsfield","year":"1990","unstructured":"Heymsfield SB, Smith R, Aulet M et al (1990) Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr 52(2):214\u2013218","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"4163_CR33","doi-asserted-by":"publisher","first-page":"F817","DOI":"10.1152\/ajprenal.2000.278.5.F817","volume":"278","author":"A Chagnac","year":"2000","unstructured":"Chagnac A, Weinstein T, Korzets A et al (2000) Glomerular hemodynamics in severe obesity. Am J Physiol Ren Physiol 278(5):F817\u2013F822","journal-title":"Am J Physiol Ren Physiol"},{"issue":"6","key":"4163_CR34","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/01.ASN.0000068462.38661.89","volume":"14","author":"A Chagnac","year":"2003","unstructured":"Chagnac A, Weinstein T, Herman M et al (2003) The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14(6):1480\u20131486","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4163_CR35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1681\/ASN.V1261211","volume":"12","author":"JR Henegar","year":"2001","unstructured":"Henegar JR, Bigler SA, Henegar LK et al (2001) Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 12(6):1211\u20131217","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4163_CR36","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/ndt\/16.9.1790","volume":"16","author":"M Praga","year":"2001","unstructured":"Praga M, Hern\u00e1ndez E, Morales E et al (2001) Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transpl 16(9):1790\u20131798","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4163_CR37","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1046\/j.1523-1755.2001.0590041498.x","volume":"59","author":"N Kambham","year":"2001","unstructured":"Kambham N, Markowitz GS, Valeri AM et al (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59(4):1498\u20131509","journal-title":"Kidney Int"},{"issue":"8","key":"4163_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrneph.2016.75","volume":"12","author":"VD D\u2019Agati","year":"2016","unstructured":"D\u2019Agati VD, Chagnac A, de Vries APJ et al (2016) Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol 12(8):453\u2013471","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"4163_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10157-020-01944-2","volume":"24","author":"H Kataoka","year":"2020","unstructured":"Kataoka H, Nitta K, Hoshino J (2020) Visceral fat and clinicopathological characteristics of obesity-related glomerulopathy. Clin Exp Nephrol 24(11):989\u2013998","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"4163_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1053\/jhep.2003.50342","volume":"38","author":"MG Emery","year":"2003","unstructured":"Emery MG, Fisher JM, Chien JY et al (2003) CYP2E1 activity before and after weight loss in morbidly obese subjects with NAFLD. Hepatology 38(2):428\u2013435","journal-title":"Hepatology"},{"issue":"2","key":"4163_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2213-8587(13)70062-7","volume":"1","author":"N Stefan","year":"2013","unstructured":"Stefan N, H\u00e4ring HU, Hu FB, Schulze MB (2013) Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 1(2):152\u2013162","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7121","key":"4163_CR42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","volume":"444","author":"JP Despr\u00e9s","year":"2006","unstructured":"Despr\u00e9s JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444(7121):881\u2013887","journal-title":"Nature"},{"issue":"9468","key":"4163_CR43","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365(9468):1415\u20131428","journal-title":"Lancet"},{"issue":"1","key":"4163_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/j.1550-8528.1997.tb00276.x","volume":"5","author":"GD Foster","year":"1997","unstructured":"Foster GD, Wadden TA, Vogt RA (1997) Resting energy expenditure in obese African American and Caucasian women. Obes Res 5(1):1\u20138","journal-title":"Obes Res"},{"issue":"4","key":"4163_CR45","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0889-8529(05)70361-3","volume":"25","author":"GA Bray","year":"1996","unstructured":"Bray GA (1996) Health hazards of obesity. Endocrinol Metab Clin North Am 25(4):907\u2013919","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"4163_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"CY Hsu","year":"2006","unstructured":"Hsu CY, McCulloch CE, Iribarren C et al (2006) Body mass index and risk for end-stage renal disease. Ann Intern Med 144(1):21\u201328","journal-title":"Ann Intern Med"},{"issue":"1","key":"4163_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.ki.5002586","volume":"73","author":"Y Wang","year":"2008","unstructured":"Wang Y, Chen X, Song Y et al (2008) Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 73(1):19\u201333","journal-title":"Kidney Int"},{"key":"4163_CR48","doi-asserted-by":"publisher","first-page":"k5301","DOI":"10.1136\/bmj.k5301","volume":"364","author":"AR Chang","year":"2019","unstructured":"Chang AR, Grams ME, Ballew SH et al (2019) Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 364:k5301","journal-title":"BMJ"},{"issue":"12","key":"4163_CR49","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1517\/17425255.2012.722757","volume":"8","author":"DR Brocks","year":"2012","unstructured":"Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS (2012) The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert Opin Drug Metab Toxicol 8(12):1505\u20131519","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"4163_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1467-789X.2009.00614.x","volume":"11","author":"R Padwal","year":"2010","unstructured":"Padwal R, Brocks D, Sharma AM (2010) A systematic review of drug absorption following bariatric surgery. Obes Rev 11(1):41\u201350","journal-title":"Obes Rev"},{"issue":"19","key":"4163_CR51","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2146\/ajhp060033","volume":"63","author":"AD Miller","year":"2006","unstructured":"Miller AD, Smith KM (2006) Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm 63(19):1852\u20131857","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"4163_CR52","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00268-021-06394-9","volume":"46","author":"E Stenberg","year":"2022","unstructured":"Stenberg E, Dos Reis Falc\u00e3o LF, O\u2019Kane M et al (2022) Guidelines for perioperative care in bariatric surgery (ERAS). World J Surg 46(4):729\u2013751","journal-title":"World J Surg"},{"issue":"11","key":"4163_CR53","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","volume":"137","author":"CA Schiavon","year":"2018","unstructured":"Schiavon CA, Bersch-Ferreira AC, Santucci EV et al (2018) Effects of bariatric surgery in obese patients with hypertension (GATEWAY). Circulation 137(11):1132\u20131142","journal-title":"Circulation"},{"issue":"9","key":"4163_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrneph.2011.92","volume":"7","author":"AA Udy","year":"2011","unstructured":"Udy AA, Roberts JA, Lipman J (2011) Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 7(9):539\u2013543","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4163_CR55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/phar.2231","volume":"39","author":"AM Cook","year":"2019","unstructured":"Cook AM, Hatton-Kolpek J (2019) Augmented renal clearance. Pharmacotherapy 39(3):346\u2013354","journal-title":"Pharmacotherapy"},{"issue":"11","key":"4163_CR56","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/phar.1653","volume":"35","author":"ALV Hobbs","year":"2015","unstructured":"Hobbs ALV, Shea KM, Roberts KM, Daley MJ (2015) Implications of augmented renal clearance on drug dosing in critically ill patients: focus on antibiotics. Pharmacotherapy 35(11):1063\u20131075","journal-title":"Pharmacotherapy"},{"issue":"4","key":"4163_CR57","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijantimicag.2017.12.015","volume":"51","author":"SAM Dhaese","year":"2018","unstructured":"Dhaese SAM, Roberts JA, Carlier M et al (2018) Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Int J Antimicrob Agents 51(4):594\u2013600","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"4163_CR58","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/cid\/ciaa224","volume":"72","author":"JA Roberts","year":"2021","unstructured":"Roberts JA, Joynt G, Lee A et al (2021) The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients (SMARRT). Clin Infect Dis 72(8):1369\u20131378","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4163_CR59","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M et al (2014) DALI: defining antibiotic levels in ICU patients. Clin Infect Dis 58(8):1072\u20131083","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4163_CR60","first-page":"371","volume":"38","author":"C Carri\u00e9","year":"2019","unstructured":"Carri\u00e9 C, Petit L, d\u2019Houdain N et al (2019) Augmented renal clearance in critically ill trauma patients. Anaesth Crit Care Pain Med 38(4):371\u2013375","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"3","key":"4163_CR61","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/cc9004","volume":"14","author":"E Macedo","year":"2010","unstructured":"Macedo E, Bouchard J, Soroko SH et al (2010) Fluid accumulation, recognition and staging of AKI in critically-ill patients. Crit Care 14(3):R82","journal-title":"Crit Care"},{"issue":"5","key":"4163_CR62","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/FTD.0000000000000432","volume":"39","author":"CJ Hodiamont","year":"2017","unstructured":"Hodiamont CJ, Janssen JM, de Jong MD et al (2017) Therapeutic drug monitoring of gentamicin peak concentrations in critically ill patients. Ther Drug Monit 39(5):522\u2013530","journal-title":"Ther Drug Monit"},{"issue":"3","key":"4163_CR63","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2215\/CJN.04071206","volume":"2","author":"IM Wahba","year":"2007","unstructured":"Wahba IM, Mak RH (2007) Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2(3):550\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"4163_CR64","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1681\/ASN.2013040330","volume":"24","author":"P Stenvinkel","year":"2013","unstructured":"Stenvinkel P, Zoccali C, Ikizler TA (2013) Obesity in CKD\u2014what should nephrologists know? J Am Soc Nephrol 24(11):1727\u20131736","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4163_CR65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ekir.2017.01.007","volume":"2","author":"N Tsuboi","year":"2017","unstructured":"Tsuboi N, Okabayashi Y, Shimizu A, Yokoo T (2017) The renal pathology of obesity. Kidney Int Rep 2(2):251\u2013260","journal-title":"Kidney Int Rep"},{"issue":"2","key":"4163_CR66","first-page":"221","volume":"69","author":"AN Friedman","year":"2017","unstructured":"Friedman AN, Quinney SK, Inker LA et al (2017) Comparative effects of recommended doses of citrate-based phosphate binders on serum FGF-23 and creatinine clearance in CKD. Am J Kidney Dis 69(2):221\u2013229","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"4163_CR67","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.kint.2016.10.019","volume":"91","author":"CP Kovesdy","year":"2017","unstructured":"Kovesdy CP, Furth SL, Zoccali C (2017) Obesity and kidney disease: hidden consequences of the epidemic. Kidney Int 91(2):260\u2013262","journal-title":"Kidney Int"},{"issue":"6","key":"4163_CR68","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1262-3636(07)70156-8","volume":"30","author":"AD Karelis","year":"2004","unstructured":"Karelis AD, Brochu M, Rabasa-Lhoret R (2004) Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab 30(6):569\u2013572","journal-title":"Diabetes Metab"},{"issue":"5","key":"4163_CR69","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17425255.2017.1290796","volume":"13","author":"C Lloret-Linares","year":"2017","unstructured":"Lloret-Linares C (2017) Pharmacokinetic considerations for patients with a history of bariatric surgery. Expert Opin Drug Metab Toxicol 13(5):493\u2013496","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"4163_CR70","first-page":"4112","volume":"58","author":"MP Pai","year":"2014","unstructured":"Pai MP, Russo A, Novelli A et al (2014) Bayesian estimation of vancomycin pharmacokinetic parameters in morbidly obese adults. Antimicrob Agents Chemother 58(7):4112\u20134119","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4163_CR71","first-page":"1167","volume":"15","author":"C Vlasschaert","year":"2020","unstructured":"Vlasschaert C, Thanabalasingam T, Su J et al (2020) Performance of estimating equations for measured GFR in adults across the body mass index spectrum. Clin J Am Soc Nephrol 15(8):1167\u20131175","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"4163_CR72","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41366-019-0476-z","volume":"44","author":"M L\u00f3pez-Mart\u00ednez","year":"2020","unstructured":"L\u00f3pez-Mart\u00ednez M, Luis-Lima S, Morales E et al (2020) The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors. Int J Obes 44(5):1129\u20131140","journal-title":"Int J Obes"},{"issue":"7","key":"4163_CR73","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/psp4.12418","volume":"8","author":"C Smit","year":"2019","unstructured":"Smit C, Wasmann RE, Goulooze SC et al (2019) A prospective clinical study characterizing the influence of morbid obesity on the pharmacokinetics of gentamicin. CPT Pharmacometrics Syst Pharmacol 8(7):440\u2013449","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"4163_CR74","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/jac\/dkaa312","volume":"75","author":"C Smit","year":"2020","unstructured":"Smit C, van Schip AM, van Dongen EPA, Br\u00fcggemann RJM, Becker ML, Knibbe CAJ (2020) Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. J Antimicrob Chemother 75(11):3286\u20133292","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"4163_CR75","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the MDRD study equation. Ann Intern Med 145(4):247\u2013254","journal-title":"Ann Intern Med"},{"issue":"1","key":"4163_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1373\/clinchem.2005.0525144","volume":"52","author":"GL Myers","year":"2006","unstructured":"Myers GL, Miller WG, Coresh J et al (2006) Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 52(1):5\u201318","journal-title":"Clin Chem"},{"issue":"6","key":"4163_CR77","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1365-2125.2008.03112.x","volume":"65","author":"S Janmahasatian","year":"2008","unstructured":"Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CMJ, Green B (2008) Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 65(6):964\u2013965","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4163_CR78","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1128\/AAC.00174-11","volume":"55","author":"MP Pai","year":"2011","unstructured":"Pai MP, Nafziger AN, Bertino JS Jr (2011) Simplified estimation of aminoglycoside pharmacokinetics in underweight, normal-weight, and overweight adults. Antimicrob Agents Chemother 55(9):4006\u20134011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4163_CR79","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1111\/jth.14948","volume":"18","author":"V Speed","year":"2020","unstructured":"Speed V, Green B, Roberts LN, Woolcombe S, Bartoli-Abdou J, Barsam S et al (2020) Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis. J Thromb Haemost 18(9):2296\u20132307","journal-title":"J Thromb Haemost"},{"issue":"6","key":"4163_CR80","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bcp.12892","volume":"81","author":"K Chairat","year":"2016","unstructured":"Chairat K, Jittamala P, Hanpithakpong W, Day NPJ, White NJ, Pukrittayakamee S et al (2016) Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol 81(6):1103\u20131112","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4163_CR81","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/clpt.2008.98","volume":"84","author":"CD Cropp","year":"2008","unstructured":"Cropp CD, Yee SW, Giacomini KM (2008) Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther 84(3):412\u2013416","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4163_CR82","first-page":"31","volume":"26","author":"DE Smith","year":"1998","unstructured":"Smith DE, Pavlova A, Berger UV et al (1998) Tubular localization and tissue distribution of peptide transporters. Drug Metab Dispos 26(1):31\u201337","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"4163_CR83","first-page":"871","volume":"53","author":"C Trumello","year":"2014","unstructured":"Trumello C, Felisaz P, Locatelli M et al (2014) Inhibition of trimethoprim on creatinine tubular secretion. Clin Pharmacokinet 53(10):871\u2013880","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"4163_CR84","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0022-5347(17)67149-0","volume":"114","author":"F Berglund","year":"1975","unstructured":"Berglund F, Killander J, Pompeius R (1975) Effect of trimethoprim-sulfamethoxazole on renal excretion of creatinine in man. J Urol 114(6):802\u2013808","journal-title":"J Urol"},{"issue":"4","key":"4163_CR85","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/clpt.1994.47","volume":"55","author":"RA Reiss","year":"1994","unstructured":"Reiss RA, Haas CE, Karki SD et al (1994) Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 55(4):392\u2013398","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4163_CR86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2165\/00002512-200016030-00002","volume":"16","author":"BA Sproule","year":"2000","unstructured":"Sproule BA, Hardy BG, Shulman KI (2000) Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 16(3):165\u2013177","journal-title":"Drugs Aging"},{"issue":"11","key":"4163_CR87","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/00007611-198511000-00031","volume":"78","author":"RW Finley","year":"1985","unstructured":"Finley RW, Bryan CS, Knight RW (1985) Lithium toxicity: review of an emerging clinical entity. South Med J 78(11):1373\u20131376","journal-title":"South Med J"},{"issue":"10","key":"4163_CR88","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S et al (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44(10):1051\u20131065","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4163_CR89","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NHG Holford","year":"1996","unstructured":"Holford NHG (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30(5):329\u2013332","journal-title":"Clin Pharmacokinet"},{"key":"4163_CR90","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4163_CR91","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","volume":"109S","author":"NHG Holford","year":"2017","unstructured":"Holford NHG, Anderson BJ (2017) Allometric size: scientific theory and extension to normal fat mass. Eur J Pharm Sci 109S:S59\u2013S64","journal-title":"Eur J Pharm Sci"},{"key":"4163_CR92","first-page":"97","volume":"20","author":"PL Bonate","year":"2018","unstructured":"Bonate PL, Howard DR (2018) Pharmacokinetics in drug development: problems and challenges in obesity research. AAPS PharmSci 20:97","journal-title":"AAPS PharmSci"},{"issue":"8","key":"4163_CR93","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1128\/AAC.00059-07","volume":"51","author":"MP Pai","year":"2007","unstructured":"Pai MP, Norenberg JP, Anderson T et al (2007) Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 51(8):2741\u20132747","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4163_CR94","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/jac\/dky310","volume":"73","author":"RL Crass","year":"2018","unstructured":"Crass RL, Dunn R, Hong J et al (2018) Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother 73(11):3081\u20133086","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"4163_CR95","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/cid\/ciy790","volume":"68","author":"RL Crass","year":"2019","unstructured":"Crass RL, Rodvold KA, Mueller BA, Pai MP (2019) Renal dosing of antibiotics: are we jumping the gun? Clin Infect Dis 68(9):1596\u20131602","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4163_CR96","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s002280050524","volume":"54","author":"LA Bauer","year":"1998","unstructured":"Bauer LA, Black DJ, Lill JS et al (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54(8):621\u2013625","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"4163_CR97","first-page":"1545","volume":"27","author":"AE Patanwala","year":"2007","unstructured":"Patanwala AE, Norris CJ, Nix DE et al (2007) Vancomycin dosing for severe MRSA pneumonia: a Monte Carlo simulation. Pharmacotherapy 27(11):1545\u20131551","journal-title":"Pharmacotherapy"},{"issue":"12","key":"4163_CR98","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/phar.1321","volume":"33","author":"DE Heble Jr","year":"2013","unstructured":"Heble DE Jr, McPherson C, Nelson MP, Hunstad DA (2013) Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy 33(12):1273\u20131277","journal-title":"Pharmacotherapy"},{"issue":"5","key":"4163_CR99","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/BF00542215","volume":"24","author":"LA Bauer","year":"1983","unstructured":"Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA (1983) Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24(5):643\u2013647","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"4163_CR100","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1128\/AAC.39.2.545","volume":"39","author":"AM Traynor","year":"1995","unstructured":"Traynor AM, Nafziger AN, Bertino JS Jr (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39(2):545\u2013548","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4163_CR101","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/phar.1531","volume":"35","author":"ED Adane","year":"2015","unstructured":"Adane ED, Herald M, Koura F (2015) Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy 35(2):127\u2013139","journal-title":"Pharmacotherapy"},{"issue":"7","key":"4163_CR102","first-page":"753","volume":"38","author":"VE Bukkems","year":"2018","unstructured":"Bukkems VE, Klein DJ, Math\u00f4t RAA et al (2018) Population pharmacokinetics of tobramycin in obese and morbidly obese patients. Pharmacotherapy 38(7):753\u2013760","journal-title":"Pharmacotherapy"},{"issue":"6","key":"4163_CR103","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1592\/phco.29.6.631","volume":"29","author":"SA Spinler","year":"2009","unstructured":"Spinler SA, Ou FS, Roe MT et al (2009) Weight-based dosing of enoxaparin in obese patients with non-ST-elevation acute coronary syndrome. Pharmacotherapy 29(6):631\u2013638","journal-title":"Pharmacotherapy"},{"issue":"11","key":"4163_CR104","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1177\/1060028020923584","volume":"54","author":"J Sebaaly","year":"2020","unstructured":"Sebaaly J, Kelley D (2020) Direct oral anticoagulants in obesity: an updated literature review. Ann Pharmacother 54(11):1144\u20131158","journal-title":"Ann Pharmacother"},{"issue":"11","key":"4163_CR105","first-page":"939","volume":"51","author":"G Egan","year":"2017","unstructured":"Egan G, Hughes CA, Ackman ML (2017) Drug dosing in obese patients on chronic anticoagulation: a scoping review. Ann Pharmacother 51(11):939\u2013953","journal-title":"Ann Pharmacother"},{"issue":"6","key":"4163_CR106","first-page":"557","volume":"26","author":"MA Buerkle","year":"2017","unstructured":"Buerkle MA, Lehrer S, Sohrabi S et al (2017) Heparin-induced thrombocytopenia. Heart Lung Circ 26(6):557\u2013564","journal-title":"Heart Lung Circ"},{"issue":"1","key":"4163_CR107","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4212\/cjhp.v68i1.1423","volume":"68","author":"G Egan","year":"2015","unstructured":"Egan G, Ensom MHH (2015) Measuring anti-factor Xa activity to monitor LMWH in obesity: a critical review. Can J Hosp Pharm 68(1):33\u201347","journal-title":"Can J Hosp Pharm"},{"key":"4163_CR108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2019.06.013","volume":"180","author":"T Ohata","year":"2019","unstructured":"Ohata T, Ueno H, Hosokawa T et al (2019) Predictors of supratherapeutic anti-Xa levels with enoxaparin in obese hospitalised patients. Thromb Res 180:110\u2013116","journal-title":"Thromb Res"},{"issue":"5","key":"4163_CR109","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1213\/ANE.0000000000001257","volume":"122","author":"DM Fisher","year":"2016","unstructured":"Fisher DM, Shafer SL, Allometry (2016) shallometry! Anesth Analg 122(5):1234\u20131236. https:\/\/doi.org\/10.1213\/ANE.0000000000001257","journal-title":"shallometry! Anesth Analg"},{"issue":"4","key":"4163_CR110","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.21.4.575","volume":"21","author":"RA Blouin","year":"1982","unstructured":"Blouin RA, Bauer LA, Miller DD et al (1982) Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21(4):575\u2013580","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4163_CR111","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00003088-198611030-00002","volume":"11","author":"DR Abernethy","year":"1986","unstructured":"Abernethy DR, Greenblatt DJ (1986) Drug disposition in obese humans. An update. Clin Pharmacokinet 11(3):199\u2013213","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4163_CR112","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/00000542-199304000-00008","volume":"78","author":"F Servin","year":"1993","unstructured":"Servin F, Farinotti R, Haberer JP, Desmonts JM (1993) Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. Anesthesiology 78(4):657\u2013665","journal-title":"Anesthesiology"},{"issue":"11","key":"4163_CR113","first-page":"650","volume":"8","author":"BJ Devine","year":"1974","unstructured":"Devine BJ (1974) Gentamicin therapy. Drug Intell Clin Pharm 8(11):650\u2013655","journal-title":"Drug Intell Clin Pharm"},{"issue":"1","key":"4163_CR114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00000542-198461010-00006","volume":"61","author":"DJ Greenblatt","year":"1984","unstructured":"Greenblatt DJ, Abernethy DR, Locniskar A et al (1984) Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61(1):27\u201335","journal-title":"Anesthesiology"},{"issue":"suppl 1","key":"4163_CR115","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/bja\/aeq312","volume":"105","author":"J Ingrande","year":"2010","unstructured":"Ingrande J, Lemmens HJM (2010) Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 105(suppl 1):i16\u2013i23","journal-title":"Br J Anaesth"},{"issue":"7","key":"4163_CR116","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1381\/0960892054621350","volume":"15","author":"HJM Lemmens","year":"2005","unstructured":"Lemmens HJM, Bernstein DP, Brodsky JB (2005) Estimating ideal body weight\u2014a new formula. Obes Surg 15(7):1082\u20131083","journal-title":"Obes Surg"},{"issue":"1","key":"4163_CR117","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1038\/s41598-019-44016-6","volume":"9","author":"S Luis-Lima","year":"2019","unstructured":"Luis-Lima S, Higueras Linares T, Henriquez-Gomez L et al (2019) The error of estimated GFR in predialysis care. Sci Rep 9(1):8071","journal-title":"Sci Rep"},{"issue":"4","key":"4163_CR118","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000469669","volume":"136","author":"P Delanaye","year":"2017","unstructured":"Delanaye P, Cavalier E, Pottel H (2017) Serum creatinine: not so simple! Nephron 136(4):302\u2013308","journal-title":"Nephron"},{"issue":"8","key":"4163_CR119","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2215\/CJN.06040611","volume":"6","author":"CY Hsu","year":"2011","unstructured":"Hsu CY, Bansal N (2011) Measured GFR as \u2018gold standard\u2019\u2014all that glitters is not gold? Clin J Am Soc Nephrol 6(8):1813\u20131814","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4163_CR120","first-page":"395","volume":"41","author":"CD Adams","year":"2018","unstructured":"Adams CD, Reuthe DD, Lazo TG (2018) Considerations for renal dosing in obese patients. Crit Care Nurs Q 41(4):395\u2013409","journal-title":"Crit Care Nurs Q"},{"issue":"4S","key":"4163_CR121","first-page":"S117","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO (2024) 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int 105(4S):S117\u2013S314","journal-title":"Kidney Int"},{"key":"4163_CR122","volume-title":"Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children","author":"GR Aronoff","year":"2007","unstructured":"Aronoff GR, Bennett WM, Berns JS et al (2007) Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th edn. ACP, Philadelphia","edition":"5"},{"issue":"8","key":"4163_CR123","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65(8):757\u2013773","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"4163_CR124","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1681\/ASN.2007020199","volume":"18","author":"LA Stevens","year":"2007","unstructured":"Stevens LA, Coresh J, Feldman HI et al (2007) Evaluation of the MDRD study equation in a large diverse population. J Am Soc Nephrol 18(10):2749\u20132757","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4163_CR125","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629\u2013637","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4163_CR126","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","volume":"99","author":"CB Pierce","year":"2021","unstructured":"Pierce CB, Mu\u00f1oz A, Ng DK et al (2021) Age- and sex-dependent clinical equations to estimate GFRs in children and young adults with CKD. Kidney Int 99(4):948\u2013956","journal-title":"Kidney Int"},{"issue":"5","key":"4163_CR127","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ndt\/gfv454","volume":"31","author":"H Pottel","year":"2016","unstructured":"Pottel H, Hoste L, Dubourg L et al (2016) An estimated GFR equation for the full age spectrum (FAS). Nephrol Dial Transpl 31(5):798\u2013806","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4163_CR128","first-page":"420","volume":"25","author":"MP Pai","year":"2012","unstructured":"Pai MP (2012) Drug dosing in obesity: a historical perspective and contemporary update. J Pharm Pract 25(4):420\u2013432","journal-title":"J Pharm Pract"},{"key":"4163_CR129","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D Du Bois","year":"1916","unstructured":"Du Bois D, Du Bois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863\u2013871","journal-title":"Arch Intern Med"},{"issue":"17","key":"4163_CR130","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317(17):1098","journal-title":"N Engl J Med"},{"issue":"4","key":"4163_CR131","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","volume":"55","author":"J Verbraecken","year":"2006","unstructured":"Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L (2006) Body surface area in normal-weight, overweight, and obese adults. Metabolism 55(4):515\u2013524","journal-title":"Metabolism"},{"issue":"3","key":"4163_CR132","doi-asserted-by":"publisher","first-page":"E586","DOI":"10.1152\/ajpendo.2001.281.3.E586","volume":"281","author":"EH Livingston","year":"2001","unstructured":"Livingston EH, Lee S (2001) Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab 281(3):E586\u2013E591","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"4163_CR133","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1475-097X.2006.00718.x","volume":"27","author":"JG Heaf","year":"2007","unstructured":"Heaf JG (2007) The origin of the 1.73 m\u00b2 body surface area normalization: problems and implications. Clin Physiol Funct Imaging 27(3):135\u2013137","journal-title":"Clin Physiol Funct Imaging"},{"issue":"7","key":"4163_CR134","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2146\/ajhp080200","volume":"66","author":"JA Demirovic","year":"2009","unstructured":"Demirovic JA, Pai AB, Pai MP (2009) Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 66(7):642\u2013648","journal-title":"Am J Health Syst Pharm"},{"issue":"suppl 4","key":"4163_CR135","doi-asserted-by":"crossref","first-page":"iv122","DOI":"10.1093\/ndt\/gft329","volume":"28","author":"A Bouquegneau","year":"2013","unstructured":"Bouquegneau A, Vidal-Petiot E, Vrtovsnik F et al (2013) MDRD vs CKD-EPI to estimate GFR in obese patients. Nephrol Dial Transpl 28(suppl 4):iv122\u2013iv130","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4163_CR136","doi-asserted-by":"crossref","first-page":"e00738","DOI":"10.1002\/prp2.738","volume":"9","author":"N Falck Larsen","year":"2021","unstructured":"Falck Larsen N, Sj\u00f8berg J, Klitgaard NA et al (2021) Dosing of vancomycin in obese patients\u2014a population pharmacokinetic study. Pharmacol Res Perspect 9(2):e00738","journal-title":"Pharmacol Res Perspect"},{"issue":"7","key":"4163_CR137","first-page":"e312","volume":"18","author":"JJ Cies","year":"2017","unstructured":"Cies JJ, Moore WS, Calaman S et al (2017) Re-evaluating the need for vancomycin dosing in morbidly obese pediatric patients. Pediatr Crit Care Med 18(7):e312\u2013e318","journal-title":"Pediatr Crit Care Med"},{"issue":"5","key":"4163_CR138","first-page":"1644","volume":"89","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Ma LY, Zhao X et al (2023) Population pharmacokinetics of apixaban in obese patients with atrial fibrillation. Br J Clin Pharmacol 89(5):1644\u20131657","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4163_CR139","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00125-011-2085-9","volume":"54","author":"S Nair","year":"2011","unstructured":"Nair S, Mishra V, Hayden K et al (2011) The four-variable MDRD formula underestimates GFR in obese type 2 diabetic individuals with CKD. Diabetologia 54(6):1304\u20131307","journal-title":"Diabetologia"},{"issue":"1","key":"4163_CR140","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20\u201329","journal-title":"N Engl J Med"},{"issue":"3","key":"4163_CR141","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","volume":"62","author":"MG Shlipak","year":"2013","unstructured":"Shlipak MG, Mattes MD, Peralta CA (2013) Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis 62(3):595\u2013603","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4163_CR142","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","volume":"65","author":"EL Knight","year":"2004","unstructured":"Knight EL, Verhave JC, Spiegelman D et al (2004) Factors influencing serum cystatin C levels other than renal function. Kidney Int 65(4):1416\u20131421","journal-title":"Kidney Int"},{"issue":"12","key":"4163_CR143","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/oby.2009.96","volume":"17","author":"N Naour","year":"2009","unstructured":"Naour N, Fellahi S, Renucci JF et al (2009) Potential contribution of adipose tissue to elevated serum cystatin C in human morbid obesity. Obesity 17(12):2121\u20132126","journal-title":"Obesity"},{"issue":"6","key":"4163_CR144","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.ajkd.2008.12.043","volume":"53","author":"S Vupputuri","year":"2009","unstructured":"Vupputuri S, Fox CS, Coresh J et al (2009) Differential estimation of CKD using creatinine vs cystatin C-based equations by BMI category. Am J Kidney Dis 53(6):993\u20131001","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"4163_CR145","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2008.638","volume":"75","author":"LA Stevens","year":"2009","unstructured":"Stevens LA, Schmid CH, Greene T et al (2009) Factors other than GFR affect serum cystatin C levels. Kidney Int 75(6):652\u2013660","journal-title":"Kidney Int"},{"issue":"1","key":"4163_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2004.09.025","volume":"38","author":"G Filler","year":"2005","unstructured":"Filler G, B\u00f6kenkamp A, Hofmann W et al (2005) Cystatin C as a marker of GFR\u2014history, indications, and future research. Clin Biochem 38(1):1\u20138","journal-title":"Clin Biochem"},{"issue":"5","key":"4163_CR147","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/MNH.0b013e328348c11f","volume":"20","author":"JQ Hudson","year":"2011","unstructured":"Hudson JQ, Nyman HA (2011) Use of estimated GFR for drug dosing in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 20(5):482\u2013491","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"12","key":"4163_CR148","first-page":"1799","volume":"28","author":"BP Kearney","year":"2014","unstructured":"Kearney BP, Mathias A, Mittan A et al (2014) PK and safety of tenofovir alafenamide in HIV-infected adults with severe renal impairment. AIDS 28(12):1799\u20131808","journal-title":"AIDS"},{"issue":"6","key":"4163_CR149","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/0002-9343(88)90310-5","volume":"84","author":"DE Salazar","year":"1988","unstructured":"Salazar DE, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84(6):1053\u20131060","journal-title":"Am J Med"},{"issue":"2","key":"4163_CR150","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","volume":"58","author":"B Green","year":"2004","unstructured":"Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58(2):119\u2013133","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4163_CR151","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ckj\/sfw070","volume":"9","author":"P Delanaye","year":"2016","unstructured":"Delanaye P, Ebert N, Melsom T et al (2016) Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1 (2016). Clin Kidney J 9(5):682\u2013699","journal-title":"Clin Kidney J"},{"issue":"9","key":"4163_CR152","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/ndt\/gfx323","volume":"33","author":"S Luis-Lima","year":"2018","unstructured":"Luis-Lima S, Escamilla-Cabrera B, Negr\u00edn-Mena N et al (2018) Iohexol plasma clearance simplified by dried blood spot testing. Nephrol Dial Transpl 33(9):1597\u20131603","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4163_CR153","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1365-2125.1984.tb02567.x","volume":"18","author":"IH Benedek","year":"1984","unstructured":"Benedek IH, Blouin RA, McNamara PJ (1984) Serum protein binding and the role of increased \u03b1\u2081-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18(6):941\u2013946","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4163_CR154","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.1365-2125.1997.00609.x","volume":"43","author":"G Cheymol","year":"1997","unstructured":"Cheymol G, Poirier JM, Carrupt PA et al (1997) Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 43(6):563\u2013570","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4163_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","volume":"52","author":"JA Roberts","year":"2013","unstructured":"Roberts JA, Pea F, Lipman J (2013) The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 52(1):1\u20138","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4163_CR156","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40262-014-0166-x","volume":"53","author":"MJE Brill","year":"2014","unstructured":"Brill MJE, van Rongen A, Houwink APIJ et al (2014) Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration. Clin Pharmacokinet 53(10):931\u2013941","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4163_CR157","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000329547","volume":"4","author":"G Wuerzner","year":"2011","unstructured":"Wuerzner G, Bochud M, Giusti V, Burnier M (2011) Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. Obes Facts 4(3):238\u2013243","journal-title":"Obes Facts"},{"issue":"3","key":"4163_CR158","doi-asserted-by":"publisher","first-page":"c224","DOI":"10.1159\/000317203","volume":"116","author":"AN Friedman","year":"2010","unstructured":"Friedman AN, Strother M, Quinney SK et al (2010) Measuring the glomerular filtration rate in obese individuals without overt kidney disease. Nephron Clin Pract 116(3):c224\u2013c234","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"4163_CR159","first-page":"213","volume":"39","author":"MR Holland","year":"2010","unstructured":"Holland MR, Bisheff M, Henderson SO (2010) The use of tenecteplase in obese patients. J Emerg Med 39(2):213\u2013217","journal-title":"J Emerg Med"},{"issue":"12","key":"4163_CR160","first-page":"e344","volume":"50","author":"AHA\/ASA","year":"2019","unstructured":"AHA\/ASA (2019) 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke 50(12):e344\u2013e418","journal-title":"Stroke"},{"issue":"9","key":"4163_CR161","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1592\/phco.22.13.1077.33529","volume":"22","author":"AW Wallace","year":"2002","unstructured":"Wallace AW, Jones M, Bertino JS Jr (2002) Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 22(9):1077\u20131083","journal-title":"Pharmacotherapy"},{"issue":"13","key":"4163_CR162","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with S aureus lower respiratory tract infections. Clin Pharmacokinet 43(13):925\u2013942","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4163_CR163","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1086\/499046","volume":"42","author":"GL Drusano","year":"2006","unstructured":"Drusano GL, Louie A, Deziel M, Gumbo T (2006) The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis 42(4):525\u2013532","journal-title":"Clin Infect Dis"},{"issue":"11","key":"4163_CR164","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP et al (2020) Therapeutic monitoring of vancomycin for serious MRSA infections: a revised consensus guideline (ASHP\/IDSA\/PIDS\/SIDP). Am J Health Syst Pharm 77(11):835\u2013864","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"4163_CR165","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","volume":"102","author":"EJ Filippone","year":"2017","unstructured":"Filippone EJ, Kraft WK, Farber JL (2017) The nephrotoxicity of vancomycin. Clin Pharmacol Ther 102(3):459\u2013469","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4163_CR166","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM et al (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity. Clin Infect Dis 49(4):507\u2013514","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4163_CR167","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1128\/AAC.00712-11","volume":"55","author":"TP Lodise","year":"2011","unstructured":"Lodise TP, Drusano GL, Butterfield JM et al (2011) Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother 55(12):5507\u20135511","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4163_CR168","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE et al (2011) IDSA clinical practice guidelines for the treatment of MRSA infections in adults and children. Clin Infect Dis 52(3):e18\u2013e55","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4163_CR169","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M et al (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 46(6):1127\u20131153. https:\/\/doi.org\/10.1007\/s00134-020-06050-1","journal-title":"Intensive Care Med"},{"issue":"6","key":"4163_CR170","first-page":"361","volume":"73","author":"JS Wang","year":"2019","unstructured":"Wang JS, Wang YH, Zhang QH et al (2019) Effect of body composition on serum digoxin concentration in obese patients. J Cardiovasc Pharmacol 73(6):361\u2013367","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"4163_CR171","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1345\/aph.1L194","volume":"43","author":"EA Nutescu","year":"2009","unstructured":"Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) LMWHs in renal impairment and obesity. Ann Pharmacother 43(6):1064\u20131083","journal-title":"Ann Pharmacother"},{"issue":"19","key":"4163_CR172","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W et al (2020) ASH 2020 guidelines for management of VTE: treatment of DVT and PE. Blood Adv 4(19):4693\u20134738","journal-title":"Blood Adv"},{"issue":"6","key":"4163_CR173","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL et al (2016) Use of DOACs in obese patients: ISTH SSC guidance. J Thromb Haemost 14(6):1308\u20131313","journal-title":"J Thromb Haemost"},{"issue":"8","key":"4163_CR174","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","volume":"19","author":"KA Martin","year":"2021","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL et al (2021) Use of direct oral anticoagulants in obesity: updated ISTH SSC communication. J Thromb Haemost 19(8):1874\u20131882","journal-title":"J Thromb Haemost"},{"issue":"2","key":"4163_CR175","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2141.2011.08826.x","volume":"155","author":"JP Patel","year":"2011","unstructured":"Patel JP, Roberts LN, Arya R (2011) Anticoagulating obese patients in the modern era. Br J Haematol 155(2):137\u2013149","journal-title":"Br J Haematol"},{"issue":"11","key":"4163_CR176","first-page":"1080","volume":"38","author":"SH Hassan","year":"2018","unstructured":"Hassan SH, Sundermann ML, Davis JE et al (2018) Phenytoin pharmacokinetics in critically ill obese patients. Pharmacotherapy 38(11):1080\u20131088","journal-title":"Pharmacotherapy"},{"issue":"7","key":"4163_CR177","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD et al (2008) Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring. Epilepsia 49(7):1239\u20131276","journal-title":"Epilepsia"},{"issue":"7","key":"4163_CR178","first-page":"810","volume":"48","author":"SA Grim","year":"2008","unstructured":"Grim SA, Romanelli F, Jennings PR et al (2008) Pharmacokinetics of methotrexate in obesity. J Clin Pharmacol 48(7):810\u2013817","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4163_CR179","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1078155221989404","volume":"28","author":"AS Bryant","year":"2022","unstructured":"Bryant AS, Chow E, Allen R et al (2022) Optimizing methotrexate dosing in patients with morbid obesity. J Oncol Pharm Pract 28(2):310\u2013316","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"4163_CR180","first-page":"1099","volume":"85","author":"HM Ackland","year":"2020","unstructured":"Ackland HM, Ferreira Filho J, Goes Lima RC et al (2020) High-dose methotrexate dosing in obese patients: PK outcomes. Cancer Chemother Pharmacol 85(6):1099\u20131107","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4163_CR181","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0041-1345(98)00248-6","volume":"30","author":"U Klotz","year":"1998","unstructured":"Klotz U, Beimling P, Bickerstaffe R et al (1998) PK\/PD considerations in the use of tacrolimus in obese transplant recipients. Transpl Proc 30(4):1295\u20131296","journal-title":"Transpl Proc"},{"issue":"6","key":"4163_CR182","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1517\/17425255.2015.1033397","volume":"11","author":"LM Andrews","year":"2015","unstructured":"Andrews LM, Riva N, de Winter BCM et al (2015) Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin Drug Metab Toxicol 11(6):921\u2013936","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"4163_CR183","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J et al (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14(6):498\u2013509","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4163_CR184","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","volume":"73","author":"JA Roberts","year":"2012","unstructured":"Roberts JA, Norris R, Paterson DL, Martin JH (2012) Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 73(1):27\u201336","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4163_CR185","first-page":"332","volume":"30","author":"JT Mathew","year":"2024","unstructured":"Mathew JT, Williams M (2024) Future directions in dosing of medications in obesity. Curr Opin Crit Care 30(4):332\u2013339","journal-title":"Curr Opin Crit Care"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04163-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:10:10Z","timestamp":1789459810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04163-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":185,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4163"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04163-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Generative AI-assisted tools were used solely to support grammar correction, improvement of readability and flow, and formatting of the manuscript. The literature review, study selection, data extraction, scientific analysis, interpretation of findings, reference selection, conclusions, and final intellectual content were performed by the author. The author reviewed and verified the final manuscript and takes full responsibility for the accuracy, integrity, and originality of the work.","order":1,"name":"Ethics","label":"Use of generative AI-assisted tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"230"}}